bpc 157 human clinical trial evidence systematic review BPC-157 and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157: A Research-Based Overview of

Body Protection Compound-157 + Thymosin Beta-4 Fragment Chemical Formula: Composite peptide blend (multiple sequences) CAS Number: Mixture (individual components vary) Molecular Weight: Composite (component-dependent) Peptide Length: Multiple peptides (varied amino acid lengths) Purity: 99.0% (validated by Certificate of Analysis for each component) Appearance: White to off-white lyophilized powder Solubility: Fully soluble in water (HO) Quality Verification: Confirmed by RP-HPLC analysis Storage Conditions: Store dry at 28 C

Age & Metabolism As people age, their bodies metabolize alcohol more slowly, making them more susceptible to higher BAC levels and increased impairment

Record the date of first vial entry and discard after 28 days regardless of remaining volume and the bacteriostatic preservation system provides a defined multi-use window, not indefinite sterility maintenance

The dry matter digestibility by kids was tested by collecting samples of faeces and feed for 5 days in the last week

The FDAs position is unambiguous: BPC-157 "lacks sufficient safety data and has not been shown to be safe or effective in humans." Key implications: Compounding pharmacies cannot legally compound medications containing BPC-157 under Section 503A or 503B Marketing with therapeutic claims violates federal law regardless of disclaimers Warning letters have been issued to companies marketing BPC-157 as a therapeutic agent WADA Prohibition The World Anti-Doping Agency classifies BPC-157 as a prohibited substance under class S0: Non-Approved Substances , effective January 2023